RIOMET Stays on Shelves: FDA Greenlights Diabetes Med Continuity
Published Date: 3/13/2025
Notice
Summary
The FDA says RIOMET oral solution (metformin) hasn’t been pulled from the market because of safety or effectiveness problems. This means generic versions can keep getting approved as long as they follow the rules. Patients and drug makers can keep counting on this medicine without any sudden changes or costs.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Generics Can Still Be Approved
The FDA found that RIOMET (metformin hydrochloride) Oral Solution, 500 mg/5 mL has not been withdrawn for safety or effectiveness. Because of that, the FDA will continue to approve abbreviated new drug applications (ANDAs) that refer to this product as long as they meet legal and regulatory requirements.
Patients Can Rely on Drug Availability
The FDA determined RIOMET (metformin hydrochloride) Oral Solution, 500 mg/5 mL was not withdrawn for safety or effectiveness, and it will not begin procedures to withdraw approvals of ANDAs that refer to this drug. You (patients who use this medicine) can expect continued access and stability for this product without sudden regulatory withdrawal.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
2026-16944, Gardenia Blue Interest Group; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by Gardenia Blue Interest Group (GBIG or petitioner), c/o Exponent, Inc., proposing that we amend our color additive regulations to expand the safe use of gardenia (genipin) blue in various foods at levels consistent with good manufacturing practice. The petition also proposes to lower the specification for arsenic in gardenia (genipin) blue.
Previous / Next Documents
Previous: 2025-04019, Information Collection; Certain Federal Acquisition Regulation Part 32 Requirements
The DoD, GSA, and NASA want to keep collecting certain info about government contracts for three more years, and they’re asking the public if this is still useful and not too much work. This affects businesses and folks involved in federal contracts, with no new costs but a chance to share feedback before July 31, 2025. It’s all about making sure the paperwork stays smart and easy!
Next: 2025-04021, Issuance of Priority Review Voucher; Rare Pediatric Disease Product; Gomekli (mirdametinib)
The FDA just gave SpringWorks Therapeutics a special priority review voucher for their rare pediatric disease drug, Gomekli (mirdametinib), approved on February 11, 2025. This voucher speeds up the review of future drug applications, helping get important medicines to kids faster. Companies can use or sell these vouchers, which can save time and money in drug approval processes.